Factors contributing to the hospitalization of patients with congestive heart failure.

OBJECTIVES This study identifies acute precipitants of hospitalization and evaluates utilization of angiotension-converting enzyme inhibitors in patients admitted with congestive heart failure. METHODS Cross-sectional chart-review study was done of 435 patients admitted nonelectively from February 1993 to February 1994 to an urban university hospital with a complaint of shortness of breath or fatigue and evidence of congestive heart failure. RESULTS The most common identifiable abnormalities associated with clinical deterioration prior to admission were acute anginal chest pain (33%), respiratory infection (16%), uncontrolled hypertension with initial systolic blood pressure > or = 180 mm Hg (15%), atrial arrhythmia with heart rate > or = 120 (8%), and noncompliance with medications (15%) or diet (6%); in 34% of patients, no clear cause could be identified. After exclusion of those who were already on a different vasodilator or who had relative contraindications, 18 (32%) of the patients with ejection fractions < or = 0.35 measured prior to admission were not taking an angiotensin-converting enzyme inhibitor on presentation to the hospital. CONCLUSIONS Interventions to improve compliance, the control of hypertension, and the appropriate use of angiotensin-converting enzyme inhibitors may prevent many hospitalizations of heart-failure patients.

[1]  L. Tavazzi,et al.  Concomitant factors of decompensation in chronic heart failure. , 1996, The American journal of cardiology.

[2]  L. Perlman,et al.  Precipitation of congestive heart failure: social and emotional factors. , 1971, Annals of internal medicine.

[3]  F. Flint The Factor of Infection in Heart Failure , 1954, British medical journal.

[4]  C M Ashton,et al.  The Association between the Quality of Inpatient Care and Early Readmission , 1995, Annals of Internal Medicine.

[5]  J. Hampton,et al.  Evidence of inadequate investigation and treatment of patients with heart failure. , 1994, British heart journal.

[6]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[7]  S. Rajfer Perspective of the pharmaceutical industry on the development of new drugs for heart failure. , 1993, Journal of the American College of Cardiology.

[8]  A. Ellrodt,et al.  Reducing Lengths of Stay in the Coronary Care Unit With a Practice Guideline for Patients With Congestive Heart Failure Insights From a Controlled Clinical Trial , 1994, Medical care.

[9]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[10]  S. Shea,et al.  Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. , 1992, The New England journal of medicine.

[11]  S. Yusuf,et al.  Patterns of Medication Use in Patients With Heart Failure: A Report From the Registry of Studies of Left Ventricular Dysfunction (SOLVD) , 1995, Southern medical journal.

[12]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[13]  R. Gillum,et al.  Epidemiology of heart failure in the United States. , 1993, American heart journal.

[14]  J. Goldberger,et al.  Prognostic factors in acute pulmonary edema. , 1986, Archives of internal medicine.